Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNTX Context Therapeutics Inc.

Closed 01-12 16:00:00 EST

1.49

-0.12

-7.45%

盘后1.48

-0.01-0.67%

19:59 EST

High1.63	Low1.47	Vol1.32M
Open1.63	D1 Closing1.61	Amplitude10.06%
Mkt Cap136.90M	Tradable Cap59.41M	Total Shares91.88M
T/O2.02M	T/O Rate3.32%	Tradable Shares39.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CNTX","market":"US","secType":"STK","nameCN":"Context Therapeutics Inc.","latestPrice":1.49,"timestamp":1768251600000,"preClose":1.61,"halted":0,"volume":1323200,"hourTrading":{"tag":"盘后","latestPrice":1.48,"preClose":1.49,"latestTime":"19:59 EST","volume":23012,"amount":34038.6784496,"timestamp":1768265995521},"delay":0,"floatShares":39871400,"shares":91879177,"eps":-0.2878,"marketStatus":"Closed","change":-0.12,"latestTime":"01-12 16:00:00 EST","open":1.63,"high":1.632,"low":1.47,"amount":2018812.98832,"amplitude":0.100621,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.2878,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768294800000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1634702400000,"exchange":"NASDAQ","adjPreClose":1.61,"preHourTrading":{"tag":"盘前","latestPrice":1.63,"preClose":1.61,"latestTime":"09:29 EST","volume":9317,"amount":15203.4778049,"timestamp":1768228198420},"postHourTrading":{"tag":"盘后","latestPrice":1.48,"preClose":1.49,"latestTime":"19:59 EST","volume":23012,"amount":34038.6784496,"timestamp":1768265995521},"volumeRatio":0.363157},"requestUrl":"/m/hq/s/CNTX","defaultTab":"news","newsList":[{"id":"2601028361","title":"Context Therapeutics Highlights T Cell Engager Pipeline Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2601028361","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601028361?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:57","pubTimestamp":1767877071,"startTime":"0","endTime":"0","summary":"Context Therapeutics ( ($CNTX) ) has provided an announcement. On January 8, 2026, Context Therapeutics updated its corporate presentation to outli...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-highlights-t-cell-engager-pipeline-strategy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-highlights-t-cell-engager-pipeline-strategy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","CNTX","BK4139","BK4539"],"gpt_icon":0},{"id":"2593510240","title":"U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart","url":"https://stock-news.laohu8.com/highlight/detail?id=2593510240","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593510240?lang=en_us&edition=fundamental","pubTime":"2025-12-22 15:49","pubTimestamp":1766389793,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Comerica, Heico, WalmartDec 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Comerica, Heico and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nL4N3XS0F2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALZN","COF","LU0187121727.USD","HEI","LU0323591593.USD","ANF","LU0689472784.USD","LEU","CYTK","AXP","CRSR","AKTX","DKNG","FLUT","APRE","CNTX","GAP","LU0052756011.USD","DRI","AIG","BOW","IE00B19Z8X17.USD","CAG","CINF","LU2242649171.HKD","ELF","AZZ","FOLD","T","BK4516","CUBE","GOOGL","LU2275660780.HKD","LU1116320737.USD","AFL","FRT","CFG","FISV","BKSY","FITB","EOSE","CMA","CCL","BMBL","FBLG","LU1951200564.SGD","ALLY","CWAN","BMRN","ASB"],"gpt_icon":1},{"id":"2592939749","title":"ADVISORY-Alert from Equity-Insider.com was published in error and has been withdrawn","url":"https://stock-news.laohu8.com/highlight/detail?id=2592939749","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592939749?lang=en_us&edition=fundamental","pubTime":"2025-12-17 01:43","pubTimestamp":1765907029,"startTime":"0","endTime":"0","summary":"ADVISORY-Alert from Equity-Insider.com was published in error and has been withdrawnAn alert on cancer drug developers was inadvertently filed off a commentary by Equity-Insider.com and tagged to Immu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA1LWBBS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRLD","RLAY","BK4505","IMNM","ONCY","CNTX","BK4007","BK4139","BK4563"],"gpt_icon":0},{"id":"2592939613","title":"Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards","url":"https://stock-news.laohu8.com/highlight/detail?id=2592939613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592939613?lang=en_us&edition=fundamental","pubTime":"2025-12-17 01:18","pubTimestamp":1765905480,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nTUA1LWBBS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","BK4563","PRLD","CNTX","RLAY","ONCY","IMNM","BK4007"],"gpt_icon":0},{"id":"2581000511","title":"Context Therapeutics Advances CT-95 and CT-202 Programs Toward Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2581000511","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581000511?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:30","pubTimestamp":1762518629,"startTime":"0","endTime":"0","summary":"Context Therapeutics Inc., a clinical-stage biopharmaceutical company, announced updates on its CT-95 and CT-202 programs at the 2025 Society for Immunotherapy of Cancer  Annual Meeting. CT-95, a mesothelin x CD3 bispecific T cell engager, is currently being evaluated in an ongoing Phase 1 trial with six patients enrolled as of October 30, 2025. No cytokine release syndrome greater than Grade 2 or dose-limiting toxicities have been observed, and dose escalation is continuing. Initial Phase 1a data is anticipated to be provided in mid-2026. For CT-202, a nectin-4 x CD3 bispecific T cell engager, preclinical data supports its advancement, with regulatory filings expected to be completed to enable a first-in-human trial in the second quarter of 2026. Results for both programs will be presented in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL9lTk4y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00B64PRP62.GBP","LU2210150020.SGD","BK4112","LU2210149790.SGD","IE00BGHQF748.EUR","CNTX","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU0314104364.USD","BK4007","NDAQ","BK4588","BK4585"],"gpt_icon":0},{"id":"2581090031","title":"Context Therapeutics Reports Improved Quarterly Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2581090031","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581090031?lang=en_us&edition=fundamental","pubTime":"2025-11-06 13:13","pubTimestamp":1762406025,"startTime":"0","endTime":"0","summary":"Context Therapeutics, Inc. ( ($CNTX) ) has released its Q3 earnings. Here is a breakdown of the information Context Therapeutics, Inc. presented to...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-reports-improved-quarterly-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-reports-improved-quarterly-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","CNTX","BK4139","BK4007","BK4539"],"gpt_icon":0},{"id":"2581702393","title":"Context Therapeutics reports Q3 results and advances lead bispecific antibody trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2581702393","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581702393?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:22","pubTimestamp":1762377727,"startTime":"0","endTime":"0","summary":"Context Therapeutics Inc. reported cash and cash equivalents of $76.9 million as of September 30, 2025, compared to $94.4 million at December 31, 2024. The company recorded a net loss of $9.7 million for the third quarter of 2025, an improvement from a net loss of $17.5 million in the same period in 2024. General and administrative expenses remained steady at $1.9 million for both the third quarters of 2025 and 2024. Other income was $0.9 million in the third quarter of 2025, down from $1.2 million in 2024, mainly due to lower interest income. Context expects its cash and cash equivalents will be sufficient to fund operations into 2027. In business developments, the company is advancing its CTIM-76 and CT-95 Phase 1 trials, with CT-95 approaching target dose levels, and plans to provide initial Phase 1a data for CT-95 in mid-2026. The preclinical program CT-202 remains in development.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDLZxVF2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0314104364.USD","CNTX","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","LU2095319765.USD","LU2210149790.SGD","BK4007","BK4588","IE00BKPKM429.USD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2581048487","title":"Context Therapeutics Inc. Q3 Basic EPS USD -0.1","url":"https://stock-news.laohu8.com/highlight/detail?id=2581048487","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581048487?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:15","pubTimestamp":1762377357,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nPLXDB0E55:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNTX"],"gpt_icon":0},{"id":"2578670172","title":"Context Therapeutics Advances in Cancer Treatment with CTIM-76 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2578670172","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578670172?lang=en_us&edition=fundamental","pubTime":"2025-10-28 07:37","pubTimestamp":1761608268,"startTime":"0","endTime":"0","summary":"Context Therapeutics, Inc. (($CNTX)) announced an update on their ongoing clinical study. Context Therapeutics, Inc. is conducting a Phase 1 clinic...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-advances-in-cancer-treatment-with-ctim-76-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/context-therapeutics-advances-in-cancer-treatment-with-ctim-76-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNTX","BK4139","BK4007","BK4539","LENZ"],"gpt_icon":0},{"id":"2578936540","title":"BRIEF-Context Therapeutics Amends Sales Deal, May Sell Up To $75 Million in Common Stock – SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2578936540","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578936540?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:29","pubTimestamp":1761337740,"startTime":"0","endTime":"0","summary":"BRIEF-Context Therapeutics Amends Sales Deal, May Sell Up To $75 Million in Common Stock – SEC FilingOct 24  - Context Therapeutics Inc CNTX.O:CONTEXT THERAPEUTICS: AMENDS SALES AGREEMENT, MAY OFFER & SELL FROM TIME TO TIME COMMON STOCK OF UP TO $75 MILLION - SEC FILINGSource text: [ID:n0001628280-25-046256]Further company coverage: CNTX.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nFWN3W548W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNTX"],"gpt_icon":0},{"id":"2578474425","title":"Context Therapeutics: Amends Sales Agreement, May Offer & Sell From Time to Time Common Stock of up to $75 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2578474425","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578474425?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:04","pubTimestamp":1761336283,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nFWN3W548W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNTX","BK4007"],"gpt_icon":0},{"id":"2573671135","title":"Context Therapeutics Announces Phase 1 Clinical Trial of CT-95 Bispecific T Cell Engager for Advanced Solid Tumors at SITC 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2573671135","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573671135?lang=en_us&edition=fundamental","pubTime":"2025-10-06 19:30","pubTimestamp":1759750258,"startTime":"0","endTime":"0","summary":"Context Therapeutics Announces Phase 1 Clinical Trial of CT-95 Bispecific T Cell Engager for Advanced Solid Tumors at SITC 2025. Context Therapeutics Inc. has announced that it will present two posters at the upcoming Society for Immunotherapy of Cancer's  40th Annual Meeting, scheduled for November 7-9, 2025, in National Harbor, Maryland. The presentations will include a \"Trial in Progress\" poster detailing the Phase 1 clinical trial of CT-95, a mesothelin-directed bispecific T cell engager  for patients with advanced solid tumors. Additionally, preclinical efficacy, safety, and pharmacokinetic data for CT-202, a dual pH-dependent Nectin-4 x CD3 bispecific TCE, will be presented. The results from these studies have not yet been presented and will be disclosed during the conference. Further information, including abstracts, is available on the SITC 40th Annual Meeting website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL18BYyK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4007","LU2095319765.USD","LU2210150020.SGD","CNTX","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4585","BK4588","NDAQ","LU0314104364.USD","IE00B64PRP62.GBP","BK4112","LU2210149790.SGD"],"gpt_icon":0},{"id":"2572636186","title":"BRIEF-Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2572636186","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572636186?lang=en_us&edition=fundamental","pubTime":"2025-10-04 05:25","pubTimestamp":1759526744,"startTime":"0","endTime":"0","summary":"BRIEF-Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule Oct 3 (Reuters) - Context Therapeutics Inc CNTX.O:CONTEXT THERAPEUTICS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING R","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nTUABLVCPJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CNTX"],"gpt_icon":0},{"id":"2572639633","title":"Context Therapeutics Grants Stock Options to New Employee as Inducement Under Nasdaq Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2572639633","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572639633?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:15","pubTimestamp":1759522556,"startTime":"0","endTime":"0","summary":"Philadelphia-based Context Therapeutics Inc.  announced on October 3, 2025, the grant of non-qualified stock options to a new employee. The award allows the employee to purchase 30,000 shares of Context's common stock at an exercise price of $0.97 per share, which reflects the closing price on the grant date. The stock options have a 10-year term and will vest over four years: one-fourth will vest on the first anniversary of the grant date, with the remaining shares vesting in equal monthly installments over the following three years, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on October 0","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nNDL9f3Fh1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU0314104364.USD","IE00B3QW5Z07.USD","CNTX","IE00BKPKM429.USD","BK4588","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","BK4007","NDAQ","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2572507992","title":"Context Therapeutics Gains 11%, Insider Trades Reap Benefit","url":"https://stock-news.laohu8.com/highlight/detail?id=2572507992","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572507992?lang=en_us&edition=fundamental","pubTime":"2025-10-03 18:16","pubTimestamp":1759486602,"startTime":"0","endTime":"0","summary":"Last week, Context Therapeutics Inc. ( NASDAQ:CNTX ) insiders, who had purchased shares in the previous 12 months were...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cntx/context-therapeutics/news/context-therapeutics-gains-11-insider-trades-reap-benefit","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cntx/context-therapeutics/news/context-therapeutics-gains-11-insider-trades-reap-benefit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4539","CNTX","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2568127914","title":"Context Therapeutics initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2568127914","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568127914?lang=en_us&edition=fundamental","pubTime":"2025-09-18 04:40","pubTimestamp":1758141612,"startTime":"0","endTime":"0","summary":"Guggenheim initiated coverage of Context Therapeutics (CNTX) with a Buy rating and $5 price target The firm’s investment thesis on the stock is cen...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/context-therapeutics-initiated-with-a-buy-at-guggenheim-thefly-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/context-therapeutics-initiated-with-a-buy-at-guggenheim-thefly-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139","CNTX","BK4539"],"gpt_icon":0},{"id":"2564801512","title":"Context Therapeutics Inc. Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2564801512","media":"Reuters","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564801512?lang=en_us&edition=fundamental","pubTime":"2025-09-02 19:32","pubTimestamp":1756812744,"startTime":"0","endTime":"0","summary":"Context Therapeutics Inc. has announced that it received an extension from The Nasdaq Stock Market LLC, granting the company an additional 180 days, until February 23, 2026, to comply with the Nasdaq Listing Rule 5550, which requires a minimum bid price of $1.00 per share. This extension follows a previous notice in February 2025, indicating that the company's stock had failed to meet the minimum closing bid price for 30 consecutive business days. Context Therapeutics plans to actively monitor its stock price and may consider options such as a reverse stock split to regain compliance. However, there is no guarantee that the company will meet the requirement by the new deadline.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context The","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDLbh7QJg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTX","BK4007"],"gpt_icon":0},{"id":"2557556119","title":"Context Therapeutics Inc. : H.c. Wainwright Cuts Target Price to $4 From $5","url":"https://stock-news.laohu8.com/highlight/detail?id=2557556119","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557556119?lang=en_us&edition=fundamental","pubTime":"2025-08-07 18:06","pubTimestamp":1754561185,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nAZN4BVWKA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CNTX"],"gpt_icon":0},{"id":"2557881635","title":"Context Therapeutics Q2 net loss widens, cash funds ops into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2557881635","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557881635?lang=en_us&edition=fundamental","pubTime":"2025-08-07 05:39","pubTimestamp":1754516357,"startTime":"0","endTime":"0","summary":"Context Therapeutics Q2 net loss widens, cash funds ops into 2027OverviewContext Q2 net loss widens to $8.8 mln from $2.3 mln last yearOutlookCash and cash equivalents total $83.5 mln, funding operati","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nPLX025DF9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTX","BK4007"],"gpt_icon":0},{"id":"2557968307","title":"Context Therapeutics Inc - Expects Its Cash and Cash Equivalents Will Continue to Fund Operations Into 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2557968307","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557968307?lang=en_us&edition=fundamental","pubTime":"2025-08-07 04:11","pubTimestamp":1754511061,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nPLX025DF9:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CNTX","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.contexttherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0387},{"period":"1month","weight":0.5047},{"period":"3month","weight":0.15},{"period":"6month","weight":1.4026},{"period":"1year","weight":0.3306},{"period":"ytd","weight":0.0952}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.052227},{"month":2,"riseRate":0.25,"avgChangeRate":-0.065627},{"month":3,"riseRate":0.5,"avgChangeRate":-0.053897},{"month":4,"riseRate":0.5,"avgChangeRate":0.023173},{"month":5,"riseRate":0.75,"avgChangeRate":0.295099},{"month":6,"riseRate":0.75,"avgChangeRate":0.233367},{"month":7,"riseRate":0.5,"avgChangeRate":-0.057392},{"month":8,"riseRate":0.75,"avgChangeRate":0.057821},{"month":9,"riseRate":0.5,"avgChangeRate":0.000078},{"month":10,"riseRate":0.75,"avgChangeRate":0.018618},{"month":11,"riseRate":0.6,"avgChangeRate":-0.036732},{"month":12,"riseRate":0.4,"avgChangeRate":-0.161685}],"exchange":"NASDAQ","name":"Context Therapeutics Inc.","nameEN":"Context Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Context Therapeutics Inc.(CNTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Context Therapeutics Inc.,CNTX,Context Therapeutics Inc.股票,Context Therapeutics Inc.股票老虎,Context Therapeutics Inc.股票老虎国际,Context Therapeutics Inc.行情,Context Therapeutics Inc.股票行情,Context Therapeutics Inc.股价,Context Therapeutics Inc.股市,Context Therapeutics Inc.股票价格,Context Therapeutics Inc.股票交易,Context Therapeutics Inc.股票购买,Context Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Context Therapeutics Inc.(CNTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}